Address And Details

One Franklin Pkwy , San Mateo, CA 94403
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

Capital appreciation. Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Fund’s investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes.

Net Asset Value

as of 5:48 PM ET 09/20/2021

Performance

  • 1 Week
  • -0.28%
  • 1 Month
  • +3.80%
  • 3 Months
  • -2.42%
  • 1 Yr Return
  • -10.77%
  • 5 Yr Return
  • +10.75%

Equity Sector Breakdown

Health 77.46%
Services 6.23%
Technology 4.95%
Finance 0.78%
ConsumerDurables n/a
Energy n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Stocks 96.71%
ForeignStocks 4.07%
Preferred 0.67%
Convertible 0.34%
Cash 0.00%
Bonds 0.00%
Other 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 17.05 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -5.43 -3.76 n/a
Beta 0.92 0.94 n/a
R Squared 0.46 0.39 n/a
Std Deviation 25.06 22.47 n/a
Sharpe Ratio 0.43 0.56 n/a

Purchase Information

as of 5:46 PM ET 09/17/2021
Minimum Initial $1000000
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +8.77%
  • +10.00%
+8.77% +10.00%
3 Year
  • +8.06%
  • +10.61%
+8.06% +10.61%
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +12.54%
  • +12.88%
+12.54% +12.88%

Top 10 Holdings

Symbol Company Name % Of Assets
GILD GILEAD SCIENCES INC 6.08%
AMGN AMGEN INC 5.27%
VRTX VERTEX PHARMACEUTICALS INC 4.64%
REGN REGENERON PHARMACEUTICALS 4.60%
ILMN ILLUMINA INC 4.09%
NVAX NOVAVAX INC 3.95%
HZNP HORIZON THERAPEUTICS PUBLIC 3.57%
BGEN BIOGEN INC 3.13%
IOVA IOVANCE BIOTHERAPEUTICS INC 3.03%
MRTX MIRATI THERAPEUTICS INC 2.54%

Recent Articles from TheStreet

Evergrande Group Lead

Cramer's Mad Money Recap: Evergrande, Debt, Delta

Jim Cramer says don't get sucked into buying the dips. He can't be bullish until everyone else turns bearish, and we're still a long way away from that.

JPMorgan Chase Lead

JPMorgan Says Stock Decline Represents Buying Opportunity

'Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip,' said JPMorgan strategist Kolanovic.

Shell Tops FTSE 100 As Q4 Earnings Top Forecasts Despite Oil Market Volatility

Shell to Sell Permian Assets to ConocoPhillips for $9.5 Billion

Shell has signed an agreement to sell its Permian basin assets to ConocoPhillips for $9.5 billion cash.